StockNews.AI
CPRX
StockNews.AI
119 days

Catalyst Pharmaceuticals to Report First Quarter 2025 Financial Results on May 7, 2025

1. Catalyst Pharmaceuticals will release Q1 2025 results on May 7, 2025. 2. A conference call for discussing these results is scheduled for May 8, 2025. 3. Catalyst is focused on rare and difficult-to-treat diseases with strong market presence. 4. The company is recognized as a successful mid-cap and a fast-growing firm. 5. Forward-looking statements indicate potential risks for future forecasts.

4m saved
Insight
Article

FAQ

Why Bullish?

Catalyst's scheduled financial reporting can drive positive sentiment, similar to previous earnings results that showed growth. Positive recognition from Forbes and Deloitte enhances investor confidence.

How important is it?

The article covers imminent earnings results, pivotal for stock valuation, and highlights Catalyst's achievements, enhancing its market position.

Why Short Term?

The immediate release of financial results could lead to quick market reactions, as seen in companies showcasing strong quarterly growth.

Related Companies

N/A
CORAL GABLES, Fla., April 22, 2025 (GLOBE NEWSWIRE) --  Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living with rare and difficult-to-treat diseases, today announced that it will release its first quarter 2025 financial results after the market close on Wednesday, May 7, 2025. Catalyst's management team will host a conference call and webcast on Thursday, May 8, 2025, at 8:30 AM ET to discuss the Company's financial results and provide a business update. Conference Call & Webcast DetailsDate: Time:   US/Canada Dial-in Number:International Dial-in Number:May 8, 20258:30 AM ET(833) 316-2483(785) 838-9284   The webcast will be accessible under the Investors section on the Company's website at www.catalystpharma.com. A webcast replay will be available on Catalyst’s website for at least 30 days following the date of the event. About Catalyst PharmaceuticalsCatalyst Pharmaceuticals, Inc. (Nasdaq: CPRX), is a biopharmaceutical company committed to improving the lives of patients with rare diseases. With a proven track record of bringing life-changing treatments to the market, we focus on in-licensing, commercializing, and developing innovative therapies. Guided by our deep commitment to patient care, we prioritize accessibility, ensuring patients receive the care they need through a comprehensive suite of support services designed to provide seamless access and ongoing assistance. Catalyst maintains a well-established U.S. presence while actively seeking to expand its global commercial footprint through strategic partnerships. Catalyst, headquartered in Coral Gables, Fla., was recognized on the Forbes 2025 list as one of America's Most Successful Mid-Cap Companies and on the 2024 Deloitte Technology Fast 500™ list as one of North America’s Fastest-Growing Companies. For more information, please visit Catalyst's website at www.catalystpharma.com.  Forward-Looking Statements This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results. A number of factors, including those factors described in Catalyst's Annual Report on Form 10-K for the fiscal year 2024 and its subsequent filings with the U.S. Securities and Exchange Commission (“SEC”), could adversely affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein, which speaks only as of this date. Source: Catalyst Pharmaceuticals, Inc.

Related News